LENZ Therapeutics to Present VIZZ at Upcoming Investor and Medical Conferences.

LENZ Therapeutics announced that management will participate in several investor and medical conferences, including the Citi's 2025 BioPharma Back to School Conference, Cantor Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Investment Conference. The conferences will feature presentations on VIZZ, a FDA-approved aceclidine-based eye drop for treating presbyopia in adults.

San Diego, Aug. 25, 2025 (GLOBE NEWSWIRE) – LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, announced that company management will participate in several upcoming investor and medical conferences. These conferences include the Citi's 2025 BioPharma Back to School Conference, Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. Additionally, the company will present at Academy 2025 Boston, featuring VIZZ in an oral podium presentation and a poster presentation.

Conferences and Presentations

- Citi's 2025 BioPharma Back to School Conference
- Date: September 2-3, 2025
- Location: Boston, MA
- Format: Fireside chat at 9:45am EDT (live audio webcast) and 1x1 investor meetings

- Cantor Global Healthcare Conference
- Date: September 4, 2025
- Location: New York City, NY
- Format: Fireside chat at 1:35pm EDT (live audio webcast) and 1x1 investor meetings

- H.C. Wainwright 27th Annual Global Investment Conference
- Date: September 9, 2025
- Location: New York City, NY
- Format: Company presentation at 11:00am EDT (live audio webcast) and 1x1 investor meetings

- Morgan Stanley 23rd Annual Global Healthcare Conference
- Date: September 10, 2025
- Location: New York City, NY
- Format: Fireside chat at 10:00am EDT (live audio webcast) and 1x1 investor meetings

- Academy 2025 Boston presented by the American Academy of Optometry
- Title: Efficacy and Performance Measures for Presbyopia Treatment with Aceclidine 1.44% Ophthalmic Solution
- Presenter: Jason Miller, OD
- Day/Time: October 8, 2025; 9:30am EDT
- Session: P-01 Clinical Optics and Biometry (Room 257 A/B); 8:15am-9:45am EDT
- Title: Clinical Confirmation of Optimal Pupil Size for Miotic Treatment of Presbyopia
- Presenter: Milton Hom, OD
- Day/Time: October 9, 2025; 4:30pm-6:30pm EDT
- Session: POS-01 Scientific Program Poster Session (Exhibit Hall)

About VIZZ™ (aceclidine ophthalmic solution) 1.44%

VIZZ is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. It is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation, causing contraction of the iris sphincter muscle to create a pinhole effect and extend depth of focus to improve vision [1].

Presbyopia

Presbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape, reducing the ability of the lens to focus incoming light from near objects onto the retina. Adults over age 50 lose, on average, 1.5 lines of near vision every six years [1].

References

[1] https://www.marketscreener.com/news/lenz-therapeutics-to-present-at-upcoming-investor-and-medical-conferences-ce7c50d8d888f42c